Still Hopeful About Migalastat, Amicus Also Pursuing Optimized Enzyme Replacement Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Amicus’ most promising candidate would improve upon Sanofi/Genzyme’s Pompe disease drug Lumizyme, but closer to the clinic is a program to combine Fabry disease candidate migalastat with an enzyme replacement therapy obtained in last year’s buyout of Callidus.